More recently, a few patents regarding the CB-CAR therapy have been approved, such as a CB-CAR-CD8+ T product for the prevention of acquired immunodeficiency syndrome (AIDS) associated lymphoma (Patent No. CN10960965-A). This evidence concerns the gene CD8A and AIDS.